242 related articles for article (PubMed ID: 38145833)
1. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
Vu TT; Kim K; Manna M; Thomas J; Remaily BC; Montgomery EJ; Costa T; Granchie L; Xie Z; Guo Y; Chen M; Castillo AMM; Kulp SK; Mo X; Nimmagadda S; Gregorevic P; Owen DH; Ganesan LP; Mace TA; Coss CC; Phelps MA
Pharmacol Res; 2024 Jan; 199():107048. PubMed ID: 38145833
[TBL] [Abstract][Full Text] [Related]
2. Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM; Vu TT; Liva SG; Chen M; Xie Z; Thomas J; Remaily B; Guo Y; Subrayan UL; Costa T; Helms TH; Irby DJ; Kim K; Owen DH; Kulp SK; Mace TA; Phelps MA; Coss CC
JCSM Rapid Commun; 2021; 4(2):232-244. PubMed ID: 34514376
[TBL] [Abstract][Full Text] [Related]
3. Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients.
Yu Y; Yan L; Huang T; Wu Z; Liu J
Aging (Albany NY); 2024 Mar; 16(6):5354-5369. PubMed ID: 38466657
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
6. Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Matsuo N; Azuma K; Murotani K; Murata D; Matama G; Kawahara A; Kojima T; Tokito T; Hoshino T
Thorac Cancer; 2023 May; 14(15):1362-1367. PubMed ID: 37037511
[TBL] [Abstract][Full Text] [Related]
7. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.
Reddel CJ; Allen JD; Ehteda A; Taylor R; Chen VM; Curnow JL; Kritharides L; Robertson G
J Thromb Haemost; 2017 Mar; 15(3):477-486. PubMed ID: 28058802
[TBL] [Abstract][Full Text] [Related]
8. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
Mu W; Katsoulakis E; Whelan CJ; Gage KL; Schabath MB; Gillies RJ
Br J Cancer; 2021 Jul; 125(2):229-239. PubMed ID: 33828255
[TBL] [Abstract][Full Text] [Related]
9. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
10. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.
Guo Y; Remaily BC; Thomas J; Kim K; Kulp SK; Mace TA; Ganesan LP; Owen DH; Coss CC; Phelps MA
Clin Cancer Res; 2024 Mar; 30(5):942-958. PubMed ID: 37921739
[TBL] [Abstract][Full Text] [Related]
11. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dynamics and quality control are altered in a hepatic cell culture model of cancer cachexia.
Visavadiya NP; Pena GS; Khamoui AV
Mol Cell Biochem; 2021 Jan; 476(1):23-34. PubMed ID: 32797334
[TBL] [Abstract][Full Text] [Related]
13. Catabolic mediators as targets for cancer cachexia.
Argilés JM; Moore-Carrasco R; Busquets S; López-Soriano FJ
Drug Discov Today; 2003 Sep; 8(18):838-44. PubMed ID: 12963320
[TBL] [Abstract][Full Text] [Related]
14. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
[TBL] [Abstract][Full Text] [Related]
15. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
16. Impact of altered endogenous IgG on unspecific mAb clearance.
Fuhrmann S; Kloft C; Huisinga W
J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
[TBL] [Abstract][Full Text] [Related]
17. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
18. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia.
Calore F; Londhe P; Fadda P; Nigita G; Casadei L; Marceca GP; Fassan M; Lovat F; Gasparini P; Rizzotto L; Zanesi N; Jackson D; Mehta S; Nana-Sinkam P; Sampath D; Pollock RE; Guttridge DC; Croce CM
Cancer Res; 2018 Dec; 78(23):6680-6690. PubMed ID: 30209066
[TBL] [Abstract][Full Text] [Related]
19. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
